Maintenance Notice (4:00 AM November 1 - 9:30 AM November 1, 2025): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.199
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 56390-09-1 | Product Number: E0840
Epirubicin Hydrochloride
×
![]()
×
Purity: >95.0%(HPLC)
Synonyms:
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
Shipping Information
|
|---|---|---|---|---|---|
| 10MG |
€106.00
|
1 | 31 |
|
|
| 50MG |
€360.00
|
7 | 27 |
|
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | E0840 |
Purity / Analysis Method 
|
>95.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__2__7H__2__9NO__1__1·HCl = 579.98 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Frozen (<0°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 56390-09-1 |
| Reaxys Registry Number | 4229251 |
| PubChem Substance ID | 468591676 |
| Merck Index (14) | 3623 |
| MDL Number | MFCD00941448 |
Specifications
| Appearance | Light yellow to Yellow to Orange powder to crystal |
| Purity(HPLC) | min. 95.0 area% |
| Specific rotation | +310 to +340 deg(C=0.05, methanol)(calcd.on anh.substance) |
| Water | max. 8.0 % |
Properties (reference)
| Melting Point | 185 °C |
| Specific Rotation | 310° (C=0.05,MeOH) |
| Maximum Absorption Wavelength | 497 nm (H__2O) |
| Solubility in water | Slightly soluble |
| Solubility (slightly sol. in) | Methanol |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H302 : Harmful if swallowed. H360 : May damage fertility or the unborn child. H340 : May cause genetic defects. H350 : May cause cancer. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. |
Related Laws:
| EC Number | 260-145-2 |
| RTECS# | QI9295750 |
Transport Information:
| HS Number | 2941900000 |
Application
Epirubicin Hydrochloride: An Anthracycline Antibiotic Cytotoxic Agent with a Better Toxicity Profile
Epirubicin hydrochloride is the 4’-epimer of the anthracycline antibiotic cytotoxic agent, doxorubicin [D4193]. The precise mechanisms of epirubicin’s cytotoxic and/or antiproliferative properties have not been completely elucidated. However, it has been reported that epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. After intercalation between DNA base pairs, epirubicin stabilizes the topoisomerase II-DNA complex, resulting in irreversible DNA strand breakage and cytocidal activity.1-3)
Epirubicin has been shown to have a better toxicity profile than doxorubicin. The formation of glucuronide conjugates, not seen with doxorubicin, is observed with epirubicin. The reason for this is thought to be the inversion of the OH group at the 4' position in epirubicin, which facilitates the reaction of glucuronyl transferase. This facilitates excretion and may contribute to the reduced toxicity of epirubicin compared to doxorubicin.4) In clinical, epirubicin hydrochloride has been used alone or in combination with other cytotoxic chemotherapeutic agents in the treatment of a variety of malignancies. (The product is for research purpose only.)
Epirubicin has been shown to have a better toxicity profile than doxorubicin. The formation of glucuronide conjugates, not seen with doxorubicin, is observed with epirubicin. The reason for this is thought to be the inversion of the OH group at the 4' position in epirubicin, which facilitates the reaction of glucuronyl transferase. This facilitates excretion and may contribute to the reduced toxicity of epirubicin compared to doxorubicin.4) In clinical, epirubicin hydrochloride has been used alone or in combination with other cytotoxic chemotherapeutic agents in the treatment of a variety of malignancies. (The product is for research purpose only.)
References
- 1) Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy
- 2) Epirubicin: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer
- 3) Epirubicin: is it like doxorubicin in breast cancer? A clinical review
- 4) Metabolism of 4′-modified analogs of doxorubicin. Unique glucuronidation pathway for 4’-epidoxorubicin
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.